NEREIDA PEREZ: Open Payments
NPI 1558138024 · LANCASTER, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,052 in 40 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $781 · 2025 $1,052
Food & beverage: $1,052
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 8 | $329 |
| Otsuka America Pharmaceutical, Inc. | 9 | $182 |
| AstraZeneca Pharmaceuticals LP | 6 | $119 |
| Lilly USA, LLC | 4 | $112 |
| HARMONY BIOSCIENCES LLC | 2 | $98 |
| Gilead Sciences, Inc. | 3 | $53 |
| GlaxoSmithKline, LLC. | 3 | $50 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $32 |
| PFIZER INC. | 1 | $22 |
| Radius Health, Inc. | 1 | $21 |
Products named: REXULTI, Wegovy, Ozempic, MOUNJARO, AIRSUPRA, WAKIX, TRELEGY ELLIPTA, JARDIANCE.
Industry payments across CA — which companies pay providers there.
